Global Generic Pharmaceutical Partnering Terms and Agreements Analysis Report 2010-2020 – ResearchAndMarkets.com
September 17, 2020DUBLIN–(BUSINESS WIRE)–The “Global Generic Pharmaceutical Partnering Terms and Agreements 2010-2020” report has been added to ResearchAndMarkets.com’s offering.
Global Generic Pharmaceutical Partnering Terms and Agreements 2010 to 2020 report provides a detailed understanding and analysis of how and why companies enter Generic Pharmaceutical partnering deals.
The report takes the reader through a comprehensive review Generic Pharmaceutical deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Generic Pharmaceutical partnering deals.
The report presents financial deal term values for Generic Pharmaceutical deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
One of the key highlights of the report is that over 700 online deal records of actual Generic Pharmaceutical deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type – that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
Key benefits
- In-depth understanding of Generic Pharmaceutical deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Generic Pharmaceutical agreements with real life case studies
- Detailed access to actual Generic Pharmaceutical contracts entered into by leading biopharma companies
- Identify most active Generic Pharmaceutical dealmakers since 2010
- Insight into terms included in a Generic Pharmaceutical partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Key Topics Covered:
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in Generic Pharmaceutical dealmaking
2.1. Introduction
2.2. Generic Pharmaceutical partnering over the years
2.3. Most active Generic Pharmaceutical dealmakers
2.4. Generic Pharmaceutical partnering by deal type
2.5. Generic Pharmaceutical partnering by therapy area
2.6. Generic Pharmaceutical partnering by technology type
2.7. Deal terms for Generic Pharmaceutical partnering
2.7.1 Generic Pharmaceutical partnering headline values
2.7.2 Generic Pharmaceutical deal upfront payments
2.7.3 Generic Pharmaceutical deal milestone payments
2.7.4 Generic Pharmaceutical royalty rates
Chapter 3 – Leading Generic Pharmaceutical deals
3.1. Introduction
3.2. Top Generic Pharmaceutical deals by value
Chapter 4 – Most active Generic Pharmaceutical dealmakers
4.1. Introduction
4.2. Most active Generic Pharmaceutical dealmakers
4.3. Most active Generic Pharmaceutical partnering company profiles
Chapter 5 – Generic Pharmaceutical contracts dealmaking directory
5.1. Introduction
5.2. Generic Pharmaceutical contracts dealmaking directory
Chapter 6 – Generic Pharmaceutical dealmaking by technology type
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
For more information about this report visit https://www.researchandmarkets.com/r/wkza9q
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900